Skip to main content

Table 1 Demographic and clinical characteristics at AAP initiation (baseline)

From: Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

Variable All patients (N = 481)
Age (years)
 Median (IQR) 75.0 (69.0–81.0)
 <  65, N (%) 53 (11.0)
 65–74, N (%) 168 (34.9)
 ≥ 75, N (%) 260 (54.1)
Comorbidities, N (%)a
 No comorbidities reported 152 (31.6)
 At least one comorbidity reported 329 (68.4)
  Any Cardiovascular event 281 (58.4)
   Hypertension 214 (44.5)
   Angina pectoris 27 (5.6)
   Myocardial infarction 24 (5.0)
   Arrhythmia 45 (9.4)
  Cerebrovascular accident 12 (2.5)
  Transient ischemic attack 8 (1.7)
  Other cardiovascular event 59 (12.3)
  Thromboembolic disease 10 (2.1)
  Any renal disorders 52 (10.8)
  Diabetes mellitusb 71 (14.8)
ECOG performance status, N (%)
 Unknown 202 (42.0)
 0 110 (22.9)
 1 134 (27.9)
 2 31 (6.4)
 3–4 4 (0.8)
Gleason score at initial prostate cancer diagnosis, N (%)
 Unknown 46 (9.6)
 ≤ 7 204 (42.4)
 ≥ 8 231 (48.0)
Laboratory parameters, median (IQR)
 PSA (ng/mL, N = 456) 56.2 (22.2–133.1)
 Alkaline phosphatase (units/L, N = 357) 119.0 (81.0–231.0)
 Lactate dehydrogenase (units/L, N = 184) 277.0 (197.5–382.5)
 Hemoglobin (g/dL, N = 375) 12.5 (10.8–13.8)
Location of metastases, N (%)
 Bone and/or lymph node metastases 429 (89.2)
  • Bone 378 (78.3)
  • Non-regional lymph node/s 63 (13.1)
  • Reginal lymph node/s 201 (41.8)
 Visceral (non-nodal soft tissue) 36 (7.5)
 Non-categorised 16 (3.3)
  1. aList of individual comorbidities is not mutually exclusive (same patient may have had two or more comorbidties). bIncludes insulin-dependent and non-insulin dependent. Abbreviations: ECOG Eastern Cooperative Oncology Group, IQR interquartile range, PSA prostate-specific antigen
\